The New Cancer Vaccine Results Are a Big Deal| Dr. David & Jeremiah Bearss

Moderna and Merck just announced major Phase 3 results for their personalized mRNA cancer vaccine.

In this episode of the Good Medicine Podcast, Dr. David Bearss and Dr. Jeremiah Bearss break down the newly announced results from the Phase 3 INTerpath-001 trial in patients with high-risk melanoma.

The trial met both of its primary endpoints, showing improvement in recurrence-free survival and distant metastasis-free survival when the individualized therapy was combined with Keytruda.

Dave and JJ explain why seeing an effect across both measures is significant, what makes a therapeutic cancer vaccine different from the vaccines most people are familiar with, and why these results could represent an important step toward personalized cancer vaccines becoming part of cancer treatment.

They also discuss what still needs to happen, who may ultimately benefit from this type of therapy, and why Dave believes there is a real clinical signal in the data.

Topics covered include:

• Moderna and Merck's new Phase 3 cancer vaccine results

• How personalized mRNA cancer vaccines work

• Therapeutic vaccines vs. traditional vaccines

• Recurrence and distant metastasis in melanoma

• What these results could mean for future cancer treatment

🎧 Listen on Spotify and Apple Podcasts

📺 Subscribe for more conversations on science, medicine, and innovation.

Thank you to our sponsors

BioHive: https://www.biohive.com

Galvan: https://galvan.sng.link/D4mh8/oe8k/litt

Follow Good Medicine Podcast

Insta: https://www.instagram.com/good.medicine.podcast/

X: https://x.com/GoodMedicinePod

TikTok: https://www.tiktok.com/@good.medicine.podcast

LinkedIn: https://www.linkedin.com/company/goodmedicinepodcast/